Report Company Directory

PMD DEVICE SOLUTIONS AB

PME African Infrastructure Opportunities

• Ford Equity International Rating and Forecast Report by Ford Equity Research

PMGC HOLDINGS INC.

• NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences by GlobeNewsWire
• PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc. by GlobeNewsWire
• PMGC Holdings Inc. Announces Strategic Share Acquisition in Micro Modular Reactor (MMR) Focused Nuclear Energy Company, Nuclea Energy Inc. by GlobeNewsWire
• PMGC Holdings Inc. Announces Reverse Stock Split Effective January 6, 2026 by GlobeNewsWire
• PMGC Holdings Inc. Announces Anticipated Reverse Stock Split by GlobeNewsWire
• AGA Precision Systems LLC Achieves Globally Recognized AS9100 Certification for Aerospace, Defense, and Space Manufacturing, Exploring Future Humanoid Robotics Integration by GlobeNewsWire
• NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries by GlobeNewsWire
• PMGC Holdings Inc. [Nasdaq: ELAB] Congratulates General Enterprise Ventures, Inc. [NYSE: CITR] on Its Uplisting to the NYSE American, Highlights Equity Stake by GlobeNewsWire
• PMGC Holdings Inc. Announces AGA Precision Systems LLC’s ITAR (International Traffic in Arms Regulations) Registration Approval by GlobeNewsWire
• PMGC Holdings Inc.’s Subsidiary, AGA Precision Systems LLC, Completes Acquisition of Indarg Engineering, Inc. Expanding Aerospace and Defense Manufacturing Platform by GlobeNewsWire

PMGC HOLDINGS INC.

• Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health by GlobeNewsWire
• Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial by GlobeNewsWire
• Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment by GlobeNewsWire
• PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company by GlobeNewsWire
• Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases by GlobeNewsWire
• PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K by GlobeNewsWire
• NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market by GlobeNewsWire
• PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules by GlobeNewsWire
• PMGC Holdings Announces Share Repurchases from Existing Shareholders by GlobeNewsWire
• Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 by GlobeNewsWire

PMI GROUP INC